IFNA1 and chronic myelogenous leukemia, BCR-ABL1 positive: Indeed, before the advent of Imatinib, IFNα was used as first-line therapy and was more active against primitive CML progenitor cells than imatinib treatment, which preferentially targeted more mature, differentiated CML progenitor cells (103).